Omada Health
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMDA research report →
Range $24 – $35
Price Chart
About the company
Omada Health, Inc. , together with its subsidiary, Physera, Inc. , provides a range of virtual care programs in the United States.
- CEO
- Sean Duffy
- IPO
- 2025
- Employees
- 946
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on OMDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $736.39M
- P/E
- 52.54
- Fwd P/E
- 23.34
- PEG
- 0.03
- P/S
- 2.33
- P/B
- 2.81
- EV/EBITDA
- 33.72
- Div Yield
- 0.00%
- Gross Margin
- 70.69%
- Op Margin
- 2.06%
- Net Margin
- 4.21%
- ROE
- 5.67%
- ROIC
- 2.51%
Latest fiscal year · YoY change
- Revenue
- $260.21M+53.2%
- Gross Profit
- $170.94M+66.2%
- Op Income
- $-11,972,000
- Net Income
- $-12,778,000+72.9%
- EPS
- $-0.22+74.1%
- OCF Growth
- +153.4%
- FCF Growth
- +144.5%
- 52W High
- $25.45
- 52W Low
- $10.28
- 50D MA
- $18.62
- 200D MA
- $17.70
- Beta
- 2.12
- RSI (14)
- 23
- Avg Volume
- 1.31M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Omada Health posted its strongest quarter ever, with 34% revenue growth and record profitability, and raised full-year 2026 guidance on stronger cardiometabolic demand and better operating leverage.· November 5, 2026
- Q3 revenue rose 34% year over year to $91 million, with GAAP gross margin of 76% and non-GAAP gross margin of 78%.
- GAAP net income was nearly $7 million and adjusted EBITDA was $12 million, both quarterly records for the company.
- Total members reached 1.13 million, up 36% year over year, with diabetes and hypertension programs driving growth.
- Management raised full-year 2026 revenue guidance to $344 million-$346 million and adjusted EBITDA guidance to $32 million-$34 million.
- Selling season is running later than usual because GLP-1 coverage decisions and rising healthcare costs are extending buyer deliberations into Q4.
Omada reported Q3 revenue of $91 million, up 34% year over year and about 4% sequentially from $88 million in Q2. GAAP gross margin was 76%, up from 66% in Q3 last year; non-GAAP gross margin was 78%, up from 68%. GAAP net income was nearly $7 million versus a GAAP net loss of about $3 million a year ago, and adjusted EBITDA was $12 million versus about negative $10 million year over year, with an adjusted EBITDA margin of about 14%. Total members reached a record 1.13 million, up 36% year over year, and trailing-12-month revenue per total member was $294 versus $280 in Q3 last year. The company ended Q3 with about $243 million in cash and cash equivalents and no debt. For full year 2026, revenue is now expected to be $344 million-$346 million, up from prior guidance of $334 million-$340 million, and adjusted EBITDA is now expected to be $32 million-$34 million, up from $21 million-$27 million. Management said Q4 revenue should be below Q3 due to normal holiday seasonality and lower new enrollments, while Q4 adjusted EBITDA should moderate from Q3 because of added R&D hiring and care team ramp for 2027 launches.
Sean Duffy said Q3 was Omada's strongest quarter ever, highlighting record revenue, gross margin progression, and profitability. He framed the results as validation of the company's mission and its cardiometabolic platform, emphasizing that members are getting real clinical benefits between doctor visits. He also reiterated the leadership transition, saying Wei-Li Shao will become CEO on January 1, 2027, while he moves to executive chair and stays focused on long-term strategy, partnerships, and mission.
Steven Cook emphasized that revenue outperformance came from strong early-quarter enrollments, a shift toward higher-value programs, and stronger engagement. He pointed to GAAP and non-GAAP gross margin expansion to 76% and 78%, respectively, driven by lower cost to serve, lower care team delivery cost, and cohort maturation; he also noted non-GAAP operating expenses improved to 64% of revenue from 65% a year ago. He said cash ended at about $243 million with no debt, and that the company is raising full-year guidance because of year-to-date performance and visibility into Q4, while expecting Q4 revenue to step down seasonally and Q4 EBITDA to moderate as R&D headcount and care staffing increase.
Analysts focused on three areas: GLP-1 market dynamics and whether employers are more likely to cover or drop coverage, the pace of 2027 covered-life growth, and whether enrollment efficiency is improving. Management said the GLP-1 market remains dynamic, employer decisions are extending the selling season, and Omada's strategy is designed to work whether employers cover GLP-1s or not through its prescribing, lifestyle support, and FlexCare offerings. On enrollment, management said year-to-date yield is up about 10% versus last year and that tactical changes like real-time onboarding, direct mail, and broader testing across channels helped conversion. Management also said it is too early to size 2027 covered lives because many late-stage deals are still being worked.
The call showed accelerating demand in Omada's core cardiometabolic categories, especially diabetes and hypertension, with longer member tenure and record revenue per member. Management also pointed to broader distribution through PBMs and health plans, including the HCSC expansion that could reach an additional estimated 1.5 million covered lives at launch in 2027. Profitability appears to be scaling faster than expected, with gross margin, net income, and adjusted EBITDA all at records and the company raising full-year guidance.
Management repeatedly said Q4 will likely be softer sequentially because new enrollments typically slow later in the year and holiday engagement is lower. The selling season is also being pushed deeper into Q4 by GLP-1 coverage decisions and rising healthcare costs, making 2027 covered-life visibility less certain. In addition, management expects higher R&D expense and some care-team ramp in Q4, which should temper EBITDA from Q3 levels.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.6%
- Shares Outstanding
- 62.04M
- Float Shares
- 51.85M
of shares held by institutions
160 13F filers
Buy/sell ratio 1.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Divisadero Street Capital Management, LP | 4.32M | ▲ 520.47K |
| Blackrock, Inc. | 3.76M | ▲ 1.54M |
| American Century Companies Inc | 3.70M | ▲ 17.15K |
| Cigna Investments Inc /New | 3.44M | 0 |
| Morgan Stanley | 3.24M | ▲ 437.08K |
| D. E. Shaw & Co., Inc. | 2.97M | ▲ 1.77M |
| Fmr LLC | 2.79M | ▲ 13.51K |
| Vanguard Capital Management LLC | 2.46M | ▲ 528.61K |
| Loomis Sayles & Co L P | 1.63M | ▲ 27.68K |
| Millennium Management LLC | 1.41M | ▼ 316.77K |
| Estuary Capital Management LP | 1.34M | ▲ 1.34M |
| Acadian Asset Management LLC | 1.25M | ▲ 935.78K |
Held by 202 ETFs
Biggest fund positions in OMDA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 4, 26 | Duffy Sean P. | other | 12,944 |
| Nov 4, 26 | Duffy Sean P. | sell | 12,944 |
| Nov 4, 26 | Duffy Sean P. | other | 12,944 |
| Oct 5, 26 | ROOT JONATHAN D | other | 694 |
| Oct 5, 26 | Klapstein Julie D | other | 549 |
| Oct 5, 26 | FETTER TREVOR | other | 751 |
| Oct 5, 26 | HILLEMAN JERYL L | other | 1,214 |
| Oct 1, 26 | Duffy Sean P. | other | 4,314 |
| Oct 1, 26 | Duffy Sean P. | other | 12,944 |
| Oct 1, 26 | Duffy Sean P. | sell | 12,944 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OMDA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on OMDA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Omada Health, Inc. (NASDAQ:OMDA) Stock Has Average Price Target of $26.33
defenseworld.net · Nov 17
Omada Health Presents AI-Powered Meal Feedback Research and 12-Month GLP-1 Care Track Outcomes at ObesityWeek 2026
globenewswire.com · Nov 16
Omada Health, Inc. (OMDA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 8
Omada: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 8
Unusual Options Volume Report: 3 Stocks Moving After Earnings
schaeffersresearch.com · Nov 6
What Omada Health (OMDA) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Compared to Estimates, Omada Health, Inc. (OMDA) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 5
Omada Health, Inc. (OMDA) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
